Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Precancerous Conditions 3Breast Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenomatous Polyposis Coli 2Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Pain 1Melanoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hypertension 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Sulindac × Clear all
NCT01761877 2023-02-10

NSAID Effects on Clinical and Imaging Breast Biomarkers

Stony Brook University

Phase 2 Completed
114 enrolled 11 charts
Breast

Breast Neoplasms, Hypertension, Inflammation, Neoplasms, Pain

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡